ArticleFuture science OA2026
TOMM5 is associated with oral cancer progression: a multi-omics analysis from single-cell atlas to in vitro validation.
Article in Future science OA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTranslocase of Outer Mitochondrial Membrane 5 (TOMM5), a mitochondrial outer membrane translocase subunit implicated in tumorigenesis, remains unexplored in oral cancer. Herein, we aimed to decipher the role of TOMM5 in oral cancer.
methodsThis study comprehensively explored the expression profile, clinical significance, and functional roles of TOMM5 in oral carcinogenesis with global RNA-seq and microarray datasets. In vitro experiments were performed for evaluating the impact of TOMM5 knockdown on the biological functions of oral cancer cells. Distribution heterogeneity of TOMM5 expression and related cellular trajectory was analyzed through scRNA-seq. The therapeutic implications of TOMM5 for oral cancer were analyzed through drug sensitivity prediction and tumor immune dysfunction and exclusion (TIDE) scoring.
resultsTOMM5 was significantly overexpressed in oral cancer tissues and demonstrated moderate diagnostic accuracy. TOMM5 knockdown significantly suppressed aggressive biological behaviors of oral cancer cells. ScRNA-seq data revealed predominant TOMM5 expression in B cells, decreasing with differentiation, and linked distinct pathway activities to specific cellular compartments. High TOMM5 expression was linked to reduced immune cell infiltration and sensitivity to Paclitaxel/Vincristine.
conclusionsOverexpressed TOMM5 shows potential as a biomarker in oral cancer, correlating with tumor progression and immune infiltration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.